Chrystal Capital Partners acted as the exclusive financial advisor to EMMAC Life Sciences Group on its £15 million raise through Convertible Loan Notes, with significant investment from Measure 8 Venture Partners.
Information on the Target
EMMAC Life Sciences Group ("EMMAC") stands as Europe's largest independent cannabis company, dedicated to advancing the cannabis industry through innovative solutions and a commitment to quality. With a significant presence in both cultivation and distribution, EMMAC is well-positioned to meet the growing demand for cannabis products across the continent.
The company has established itself as a leader in the sector, supported by a robust portfolio of assets and partnerships that enhance its operational capabilities. The recent fundraising through Convertible Loan Notes (CLN) will further empower EMMAC to expand its projects and reinforce its market position amidst increasing competition.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the United Kingdom
The cannabis industry in the United Kingdom has experienced significant shifts in recent years, particularly since the legalization of medical cannabis in 2018. This regulatory c
Similar Deals
Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV → Oxford Endovascular
2023
Lonsdale Capital Partners → Todays Dental
2023
University of Oxford Isis Fund I and Parkwalk Funds → Brainomix
2023
University of Oxford Isis Fund I → Oxtex
2023
東京大学協創プラットフォーム開発株式会社 → STORM Therapeutics Ltd
2023
Chrystal Capital Partners LLP
invested in
EMMAC Life Sciences Group
in 2023
in a Venture Debt deal
Disclosed details
Transaction Size: $19M